Zipsor

Type: Product
Name: Zipsor
First reported Apr 14 2014 - Updated Apr 15 2014 - 1 reports

Depomed : Announces Settlements with Two Gralise® ANDA Filers

/PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced it has entered into settlement agreements with two of the three defendants involved in Depomed's ongoing patent infringement litigation against filers of Abbreviated New Drug Applications (ANDAs) ... [Published 4 Traders - Apr 14 2014]
First reported Apr 09 2014 - Updated Apr 09 2014 - 1 reports

Chicago (North), IL; Specialty Sales Representative

OverviewinVentiv Health offers best-in-class Clinical, Consulting and Commercial services to global companies seeking to accelerate performance. With 13,000 employees in 40 countries, we rapidly transform promising ideas into commercial reality. inVentiv ... [Published PharmaDiversity - Apr 09 2014]
First reported Mar 25 2014 - Updated Mar 25 2014 - 1 reports

Depomed A 'Turtle' Gaining In Specialty Pharma Race

Of the four drugs in its product portfolio, three were acquired since 2012. The most recent, migraine drug Cambia, was bought in December from Nautilus Neurosciences for $48.7 million.Cambia may eventually become a runner-up to Depomed's No. 1 drug, Gralise, ... [Published Nasdaq - Mar 25 2014]
First reported Mar 19 2014 - Updated Mar 19 2014 - 1 reports

Depomed Earns $10 Million Milestone for FDA Approval of Mallinckrodt's XARTEMIS XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII)

/PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO ) today announced that the U.S. Food and Drug Administration (FDA) approved Mallinckrodt plc's New Drug Application (NDA) for XARTEMIS™ XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets ... [Published FirstWord Pharma - Mar 19 2014]
First reported Mar 18 2014 - Updated Mar 18 2014 - 1 reports

DEPOMED : Posts 4th Quarter and Full Year 2013 Financial Results

Depomed, Inc. reported financial results for the quarter and 12 months ended December 31, 2013 .In a release on March 12 , the Company reported that 2013 business and financial highlights include:_2013 Business Highlights:_In October, sold interests in ... [Published 4 Traders - Mar 18 2014]
Entities: Depomed Inc, Zipsor, Gralise
First reported Mar 14 2014 - Updated Mar 14 2014 - 1 reports

Put This Specialty Pharma In Your Portfolio

SummaryManagement has done a fantastic job of building a specialty pharma business. Revenue growth in 2014 should be over 50%. On a peer-valuation, the stock is attractively valued. Target is $16.On March 12, 2014, Depomed, Inc. ( DEPO ) reported financial ... [Published Seeking Alpha - Mar 14 2014]
First reported Mar 12 2014 - Updated Mar 13 2014 - 1 reports

Depomed Swings To Profit, Outlook Strong; Stock Up - Update

Drug maker Depomed Inc (DEPO: Quote), Wednesday reported a surprise profit for the fourth quarter compared with a loss last year, due to higher revenue including that related to a October royalty deal with PDL Biopharma. The results crushed Wall Street ... [Published RTTNews.com - Mar 12 2014]
First reported Mar 13 2014 - Updated Mar 13 2014 - 2 reports

Morning Movers in Biotech: Actavis plc, DepoMed, Inc. and Horizon Pharma, Inc.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.Let's take a look at the top stories in biotech and health care this morning ... [Published Motley Fool - Mar 13 2014]
First reported Mar 12 2014 - Updated Mar 12 2014 - 2 reports

DepoMed Management Discusses Q4 2013 Results - Earnings Call Transcript

4:30 PM ETOperatorGood afternoon, everyone, and welcome to the DepoMed year end financial results conference call. [Operator Instructions] Please also note that today's event is being recorded. At this time, I'd like to turn the conference call over to ... [Published Seeking Alpha - Mar 12 2014]
Entities: Depomed Inc, Gralise, Zipsor

Quotes

...has a growing product suite, its own sales force and a lot of cash," said Jason Napodano, senior biotech analyst with Zacks Investment Research. "It has the makings of a nice, steady, small specialty pharmaceutical company."
...has contributed to this important new therapy option for patients and their physicians," said Jim Schoeneck , President and CEO of Depomed.  "We expect to receive significant recurring royalty revenue from Mallinckrodt's commercialization of XARTEMIS XR.  Mallinckrodt has also licensed the Acuform delivery technology under equivalent royalty and milestone terms for its MNK-155 product candidate, which has been studied for moderate to severe acute pain.  Mallinckrodt has indicated that it expects to file an NDA for MNK-155 in the second half of their 2014 fiscal year.  FDA acceptance of the MNK-155 NDA would trigger a $5 million milestone payment to Depomed and approval by the FDA would trigger an additional $10 million milestone payment to Depomed."
...also significant, as evidenced by steady prescription growth throughout 2013 for Gralise and the subsequent growth of Zipsor," continued Schoeneck. "As we enter 2014, we are focused on continuing to grow our product sales and evaluating additional acquisitions of marketed products to add to our existing portfolio."
"We recognize that patients with breakthrough cancer pain face many challenges, including reimbursement and access issues" said Jim Schoeneck President

More Content

All (15) | News (14) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Depomed : Announces Settlements with Two Gralis... [Published 4 Traders - Apr 14 2014]
Chicago (North), IL; Specialty Sales Representa... [Published PharmaDiversity - Apr 09 2014]
Pensacola, FL - Specialty Sales Representative [Published PharmaDiversity - Apr 01 2014]
Phoenix West, AZ-Pharmaceutical Sales Represent... [Published PharmaDiversity - Mar 26 2014]
Depomed A 'Turtle' Gaining In Specialty Pharma ... [Published Nasdaq - Mar 25 2014]
Depomed Earns $10 Million Milestone for FDA App... [Published FirstWord Pharma - Mar 19 2014]
DEPOMED : Posts 4th Quarter and Full Year 2013 ... [Published 4 Traders - Mar 18 2014]
Put This Specialty Pharma In Your Portfolio [Published Seeking Alpha - Mar 14 2014]
Morning Movers in Biotech: Actavis plc, DepoMed... [Published Motley Fool - Mar 13 2014]
Morning Movers in Biotech: Actavis plc, DepoMed... [Published Motley Fool Discussion Boards - Mar 13 2014]
DepoMed Management Discusses Q4 2013 Results - ... [Published Seeking Alpha - Mar 12 2014]
Depomed Swings To Profit, Outlook Strong; Stock... [Published RTTNews.com - Mar 12 2014]
Depomed Earns $10 Million Milestone for FDA App... [Published Yahoo! Finance - Mar 12 2014]
Depomed Announces the Launch of Lazanda® (fenta... [Published PR Newswire - Oct 28 2013]
Depomed buys US & Canadian right of Lazanda nas... [Published PharmaBiz - Jul 31 2013]
1
Content Volume
Document Volume
Network
Network

Press Releases

sort by: Date | Relevance
Depomed Announces the Launch of Lazanda® (fenta... [Published PR Newswire - Oct 28 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.